Novo Nordisk punts $550 million on deal with Replicate
Looking to expand its portfolio, Danish pharma major Novo Nordisk (NOV: N) has entered into a multi-year collaboration with Replicate Bioscience, a clinical-stage company pioneering next-generation self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas.
The collaboration unites Novo Nordisk's deep therapeutic knowledge and drug development expertise with San Diego-based Replicate's novel srRNA platform to develop new therapeutic candidates to treat obesity, type 2 diabetes and other cardiometabolic diseases.
The centerpiece of the partnership is Replicate’s self-replicating RNA platform. This an mRNA construct that includes cellular machinery to make copies of an mRNA therapy after it has been dosed and is inside the cell, with the aim of amplifying the effective therapeutic dose in comparison to traditional mRNA therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze